Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vivo Ultrasound Molecular Imaging in the Evaluation of Complex Ovarian Masses: A Practical Guide to Correlation with Ex Vivo Immunohistochemistry.

Advanced biology·2023
Same author

Practical Tips and a Template for Developing Your Curriculum Vitae.

Academic radiology·2023
Same author

Defining the Roles and Responsibilities for the Vice Chair for Academic Affairs/Faculty Development in Radiology.

Academic radiology·2023
Same author

Toward Reduction in False-Positive Thyroid Nodule Biopsies with a Deep Learning-based Risk Stratification System Using US Cine-Clip Images.

Radiology. Artificial intelligence·2022
Same author

Automated Identification and Measurement Extraction of Pancreatic Cystic Lesions from Free-Text Radiology Reports Using Natural Language Processing.

Radiology. Artificial intelligence·2022
Same author

Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: <i>AJR</i> Expert Panel Narrative Review.

AJR. American journal of roentgenology·2021
Same journal

Transformative Role of Advanced Neural Computation in Clinical Image Diagnostics: A Review of Key Concepts and Applications.

Seminars in ultrasound, CT, and MR·2026
Same journal

Clinical Applications of High-Frequency Ultrasound (HFUS) in Filler Identification and Complication Management.

Seminars in ultrasound, CT, and MR·2026
Same journal

Imaging of Adrenal and Extra-Adrenal Paraganglioma.

Seminars in ultrasound, CT, and MR·2026
Same journal

Greater, lesser and third occipital nerve entrapment: Sonographic anatomy and imaging.

Seminars in ultrasound, CT, and MR·2026
Same journal

Pancreatic Neuroendocrine Neoplasms.

Seminars in ultrasound, CT, and MR·2026
Same journal

Small Bowel Neuroendocrine Neoplasms.

Seminars in ultrasound, CT, and MR·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Understanding transient hepatic attenuation differences.

Terry S Desser1

  • 1Department of Radiology, Stanford University Medical Center, Stanford, CA 94305, USA. desser@stanford.edu

Seminars in Ultrasound, CT, and MR
|October 22, 2009
PubMed
Summary
This summary is machine-generated.

Transient hepatic attenuation differences (THADs) are imaging findings caused by blood flow variations. Recognizing their typical appearance helps distinguish these pseudolesions from actual liver masses.

More Related Videos

Imaging and Quantification of the Hepatic Vasculature of Mice Using Ultrafast Doppler Ultrasound
07:03

Imaging and Quantification of the Hepatic Vasculature of Mice Using Ultrafast Doppler Ultrasound

Published on: July 19, 2024

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Related Experiment Videos

Last Updated: Jun 19, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Imaging and Quantification of the Hepatic Vasculature of Mice Using Ultrafast Doppler Ultrasound
07:03

Imaging and Quantification of the Hepatic Vasculature of Mice Using Ultrafast Doppler Ultrasound

Published on: July 19, 2024

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Area of Science:

  • Radiology
  • Hepatology
  • Medical Imaging

Background:

  • Transient hepatic attenuation differences (THADs) represent regional variations in liver blood flow.
  • These variations involve the balance between hepatic arterial, portal venous, and other blood inflow sources.
  • THADs are often associated with diminished portal venous inflow.

Purpose of the Study:

  • To describe the imaging characteristics and physiological basis of THADs.
  • To aid in differentiating THADs from true hepatic lesions.

Main Methods:

  • Review of imaging findings in patients with THADs.
  • Correlation of imaging appearance with hepatic blood flow dynamics.

Main Results:

  • THADs typically appear as wedge-shaped, hypervascular regions during the hepatic arterial phase.
  • These regions become isodense during venous and delayed imaging phases.
  • THADs are frequently observed in cases of localized reduced portal venous flow.

Conclusions:

  • Understanding the characteristic imaging patterns and underlying physiology of THADs is crucial.
  • This knowledge facilitates the distinction of THADs, which are pseudolesions, from true space-occupying hepatic masses.